GEN Exclusives

More »

GEN News Highlights

Back to Item »

Apogenix Obtains Roughly $3.66M to Further Cancer and Inflammatory Disease Initiatives

Focus is on developing IL-4 and CD95 ligand inhibitors, and lead candidate is expected to enter a Phase II glioblastoma trial in 2010.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Megamerger Dealzapoppin Poll

What company not in this week’s M&A headlines do you think will be at the center of a megamerger, acquisition, or partial selloff this year?